Why the study?
Is treating ACS patients with ticagrelor for 12 months cost-effective compared with generic clopidogrel?
Is treating ACS patients with ticagrelor for 12 months cost-effective compared with generic clopidogrel?
Treating ACS patients with ticagrelor for 12 months is highly cost-effective compared to generic clopidogrel, with a cost per QALY gained well below generally accepted thresholds.
No takes yet. Share an insight, caveat, or question.
May support ticagrelor in ACS on cost-effectiveness grounds; extends economic models but should not yet change practice.
Nikolic et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: